<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166439">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01836198</url>
  </required_header>
  <id_info>
    <org_study_id>14586</org_study_id>
    <secondary_id>I1R-MC-GLBZ</secondary_id>
    <nct_id>NCT01836198</nct_id>
  </id_info>
  <brief_title>The Effect of Gemfibrozil, Ketoconazole and Clarithromycin on the Amount of LY2409021 in the Bloodstream</brief_title>
  <official_title>Effects of Potent Inhibition of CYP2C8, CYP2J2, and CYP3A4, Using Gemfibrozil, Ketoconazole, and Clarithromycin as Probes, on the Pharmacokinetics of LY2409021 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effect of gemfibrozil, ketoconazole, and
      clarithromycin on how much LY2409021 is found in the bloodstream and how long the body takes
      to get rid of it. The study is split into two parts, Part A and Part B. Participants in Part
      A are divided into two cohorts (groups).  Each cohort will participate in two study periods.
      Period one involves a single dose of LY2409021. Period two involves either gemfibrozil or
      ketoconazole for 21 days with LY2409021 given once on Day 4. Part A will last for 51 days
      and will also involve screening within 27 days of the start of the study. Part B is only
      open to participants who successfully completed Part A of the study. Participants in Part B
      will receive one single dose of LY2409021 on Day 4 and clarithromycin for 21 days. Part B
      will last for 29 days and will also involve screening within 27 days of the start of the
      study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part B was added to the trial in August 2013, per protocol amendment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Pharmacokinetics: Maximum Concentration (Cmax) of LY2409021</measure>
    <time_frame>Predose of LY2409021 up to Day 28 in each Part</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY2409021</measure>
    <time_frame>Predose of LY2409021 up to Day 28 in each Part</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>LY2409021 Only (Cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A, Period 1. Participants will receive a single oral 20 mg dose of LY2409021 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2409021+Gemfibrozil (Cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A, Period 2. Participants will receive a morning (AM) and evening (PM) oral dose of 600 milligram (mg) gemfibrozil on Days 1-20 and an AM oral dose only of 600 mg gemfibrozil on Day 21. Participants will also receive a single 20 mg oral dose of LY2409021 on Day 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2409021 Only (Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A, Period 1. Participants will receive a single oral 20 mg dose LY2409021 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2409021+Ketoconazole (Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A, Period 2. Participants will receive a 400 mg oral dose of ketoconazole on Days 1-21 and a single oral dose of 20 mg LY2409021 on Day 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2409021+Clarithromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B. Participants will receive a 500 mg oral dose of clarithromycin on Days 1-21 and a single oral dose of 20 mg LY2409021 on Day 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2409021</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY2409021 Only (Cohort 1)</arm_group_label>
    <arm_group_label>LY2409021+Gemfibrozil (Cohort 1)</arm_group_label>
    <arm_group_label>LY2409021 Only (Cohort 2)</arm_group_label>
    <arm_group_label>LY2409021+Ketoconazole (Cohort 2)</arm_group_label>
    <arm_group_label>LY2409021+Clarithromycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemfibrozil</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY2409021+Gemfibrozil (Cohort 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketoconazole</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY2409021+Ketoconazole (Cohort 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY2409021+Clarithromycin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants are overtly healthy males or females, as determined by medical history
             and physical examination

          -  Participants have a body mass index (BMI) of 18.0 to 32.0 kilogram per meter square
             (kg/m^2), inclusive, at screening

          -  Participants have a fasting blood glucose of 54 to 110 milligram per deciliter
             (mg/dL) (3.0 to 6.1 micromole per liter [mmol/L])

        Exclusion Criteria:

          -  Participants that have a contraindication to use of clarithromycin

          -  Participants that have a personal or family history of long QT syndrome

          -  Participants with a family history of sudden unexplained death or cardiac death in an
             immediate family member under 60 years of age

          -  Participants with a personal history of unexplained syncope within the last year

          -  Participants who have taken drugs or substances known to be an inducer or inhibitor
             of cytochrome P450 (CYP)3A4 or CYP2C8 or CYP2J2 (for example, St. John's wort,
             rifampin, ketoconazole, trimethoprim) within 30 days prior to the first dose
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 27, 2013</lastchanged_date>
  <firstreceived_date>April 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gemfibrozil</mesh_term>
    <mesh_term>Ketoconazole</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
